Why did Stryker's reported earnings grow much less than its adjusted earnings in Q2 2025?

Reported results include significant non-recurring and non-cash items excluded from adjusted figures. In Q2 2025, these included $65 million of inventory step-up from acquisitions, $187 million of intangible amortization, $55 million of goodwill and other impairments, and $58 million of other acquisition and integration costs. Reported diluted EPS of $2.29 rose 7.0%, versus adjusted EPS of $3.13 rising 11.4%.

How much did the Inari acquisition and Spinal divestiture affect Orthopaedics and overall growth?

The divested Spinal implant business sharply reduced Orthopaedics reported growth. Reported Orthopaedics sales rose just 2.0%, but excluding Spinal, growth was 10.7% reported and 9.7% constant currency. Organic Orthopaedics growth was 9.0%. Inari, which drove the Vascular growth within MedSurg and Neurotechnology, contributed to the 5.7-point acquisition benefit in that segment.

Is Stryker's raised guidance a sign of strong momentum, and what are the key risks?

The raised guidance reflects strong demand, durable innovation, and operational execution, and tariff estimates improved. Risks include a rise in leverage after the acquisition spending, ongoing tariff and trade-policy uncertainty, FX volatility, potential product recall and regulatory costs, and integration risks related to Inari. The company also notes it cannot reliably forecast the timing of certain special charges, which could be material.

What does the balance sheet change mean for investors?

Long-term debt increased by about $2.6 billion to $14.8 billion, and cash dropped to $2.4 billion from $3.7 billion at year-end 2024. Net cash from operations was $1.36 billion for the six months, up from $837 million, but operating cash flow after capital expenditures and dividends was still lower than the acquisition outlay, so the company relied on new borrowings. Inventories also grew to $5.3 billion from $4.8 billion, which investors should monitor for working-capital efficiency.

What should investors watch for in upcoming quarters?

Investors should watch whether MedSurg and Neurotechnology keeps double-digit organic growth, particularly in Vascular and Endoscopy, and whether Orthopaedics maintains its roughly 9% organic growth. They should also track whether the company delivers the $13.40–$13.60 adjusted EPS guidance given reported earnings pressure, the pace of debt reduction, the realized tariff cost versus the $175 million estimate, and any further recall or regulatory charges.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.

Stryker reported strong second quarter 2025 results on July 31, 2025, with reported net sales up 11.1% to $6.0 billion^a and organic net sales up 10.2%, driven by 9.7% unit volume growth and 0.5% from pricing.

MedSurg and Neurotechnology was the standout, growing 17.3% reported and 11.0% organic, led by Vascular (up 52.3% in the U.S., boosted by the Inari acquisition) and Endoscopy. Orthopaedics grew only 2.0% reported due to the divested Spinal implant business, but rose 9.0% organically and 10.7% excluding Spinal in the quarter. Reported diluted EPS rose 7.0% to $2.29^b, while adjusted EPS rose 11.4% to $3.13, and adjusted operating margin expanded 110 bps to 25.7%.

Management raised full-year 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted diluted EPS of $13.40 to $13.60^c. The company estimates a net 2025 tariff impact of about $175 million, lower than before due to reduced U.S.-China tariffs and the proposed U.S.-EU tariff framework. Reported results carry notable pressure: reported operating income for the six months fell 3.6%, reported net earnings fell 4.6%, and reported EPS declined 5.0%, mainly because of acquisition-related charges, amortization, and impairments.

Balance sheet leverage rose sharply, with long-term debt climbing to $14.8 billion^d from $12.2 billion at year-end 2024, following about $4.8 billion of acquisition spending (including Inari). Cash fell to $2.4 billion, and inventories rose to $5.3 billion, a potential watch item.

02—Key points

Key Highlights

Reported net sales rose 11.1% to $6.02 billion in Q2 2025 (10.2% organic), with U.S. sales up 12.5% and International up 6.8%.
MedSurg and Neurotechnology sales grew 17.3% reported (11.0% organic), with Vascular up 52.3% in the U.S. following the Inari acquisition.
Adjusted EPS rose 11.4% to $3.13 and adjusted operating margin expanded 110 bps to 25.7%, while reported diluted EPS rose 7.0% to $2.29.
Full-year 2025 guidance raised: organic sales growth of 9.5%–10.0% and adjusted diluted EPS of $13.40–$13.60.
Estimated 2025 net tariff impact reduced to about $175 million, reflecting lower U.S.-China tariffs and the proposed U.S.-EU framework.
Six-month reported operating income fell 3.6% and net earnings fell 4.6%, driven by acquisition costs, amortization, and impairments.
Long-term debt rose to $14.8 billion from $12.2 billion at year-end 2024 after roughly $4.8 billion in acquisition spending, and cash declined to $2.4 billion.

03—Questions

Frequently Asked Questions

Why did Stryker's reported earnings grow much less than its adjusted earnings in Q2 2025?
Reported results include significant non-recurring and non-cash items excluded from adjusted figures. In Q2 2025, these included $65 million of inventory step-up from acquisitions, $187 million of intangible amortization, $55 million of goodwill and other impairments, and $58 million of other acquisition and integration costs. Reported diluted EPS of $2.29 rose 7.0%, versus adjusted EPS of $3.13 rising 11.4%.
How much did the Inari acquisition and Spinal divestiture affect Orthopaedics and overall growth?
The divested Spinal implant business sharply reduced Orthopaedics reported growth. Reported Orthopaedics sales rose just 2.0%, but excluding Spinal, growth was 10.7% reported and 9.7% constant currency. Organic Orthopaedics growth was 9.0%. Inari, which drove the Vascular growth within MedSurg and Neurotechnology, contributed to the 5.7-point acquisition benefit in that segment.
Is Stryker's raised guidance a sign of strong momentum, and what are the key risks?
The raised guidance reflects strong demand, durable innovation, and operational execution, and tariff estimates improved. Risks include a rise in leverage after the acquisition spending, ongoing tariff and trade-policy uncertainty, FX volatility, potential product recall and regulatory costs, and integration risks related to Inari. The company also notes it cannot reliably forecast the timing of certain special charges, which could be material.
What does the balance sheet change mean for investors?
Long-term debt increased by about $2.6 billion to $14.8 billion, and cash dropped to $2.4 billion from $3.7 billion at year-end 2024. Net cash from operations was $1.36 billion for the six months, up from $837 million, but operating cash flow after capital expenditures and dividends was still lower than the acquisition outlay, so the company relied on new borrowings. Inventories also grew to $5.3 billion from $4.8 billion, which investors should monitor for working-capital efficiency.
What should investors watch for in upcoming quarters?
Investors should watch whether MedSurg and Neurotechnology keeps double-digit organic growth, particularly in Vascular and Endoscopy, and whether Orthopaedics maintains its roughly 9% organic growth. They should also track whether the company delivers the $13.40–$13.60 adjusted EPS guidance given reported earnings pressure, the pace of debt reduction, the realized tariff cost versus the $175 million estimate, and any further recall or regulatory charges.

04—Continue

← View all 8-K filings